Comparative Pharmacology
Head-to-head clinical analysis: ARNUITY ELLIPTA versus NASACORT HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARNUITY ELLIPTA versus NASACORT HFA.
ARNUITY ELLIPTA vs NASACORT HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. This reduces airway inflammation and hyperresponsiveness.
Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators (e.g., cytokines, prostaglandins) and reducing nasal inflammation.
1 inhalation (100 mcg fluticasone furoate) once daily via oral inhalation, with or without a spacer.
55 mcg (1 spray) per nostril once daily; may increase to 110 mcg (2 sprays) per nostril once daily if needed. Maximum 440 mcg/day total.
None Documented
None Documented
The terminal elimination half-life of fluticasone furoate is approximately 24 hours. This long half-life supports once-daily dosing and contributes to sustained anti-inflammatory effects in the lungs.
Terminal elimination half-life is approximately 3.5 hours following intranasal administration, reflecting slow systemic absorption and prolonged local retention.
Fluticasone furoate is eliminated primarily via hepatic metabolism and subsequent biliary excretion. Following oral administration, approximately 90% of the dose is excreted in feces as metabolites, with less than 1% excreted unchanged in urine. Renal excretion of unchanged drug is negligible.
Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites and parent drug)
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid